| ALLIGATOR BIOSCIENCE |
| Schweden |
| Gesundheit |
| SE0024173637 / A41BED |
| 7AL0 (Frankfurt) |
| FRA:7AL0, ETR:7AL0, 7AL0:GR |
| - |
| https://alligatorbioscien.. |
|
Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs, particularly those targeting the CD40 receptor pathway. Its primary purpose is to activate the patient's immune sys..
>Volltext.. |
| 8.2 Mio. EUR |
| 6.47 Mio. EUR |
| 0.05 Mio. EUR |
| -11.3 Mio. EUR |
| -4.76 Mio. EUR |
| -0.1 EUR |
| 4 Mio. EUR |
| 5.76 Mio. EUR |
| -14.45 Mio. EUR |
| 0.8 |
| -99.06% |
| 76.74% |
| - |
| - |
| - |
| - |
| ALLIGATOR BIOSCIENCE, ALLIGATOR BIO |
| 08.04.26 |
|